Drug intelligence / Profile preview

dextromethorphan + promethazine

Development stage
Approved
Lead developer
Sanofi
Modality
Small Molecules
Administration
Oral
01

Overview

Dextromethorphan + promethazine is an oral combination drug comprising a **cough suppressant** (dextromethorphan) and a **first-generation antihistamine** (promethazine) used primarily for the **temporary relief of cough and upper respiratory symptoms** associated with allergies or the common cold[1][2][3][5][6][7][11]. - **Promethazine** acts as an H1 histamine receptor antagonist, providing antihistaminic, sedative, and antiemetic effects[3][6][8][9]. - **Dextromethorphan** is an antitussive agent that elevates the cough threshold by acting on the central nervous system[3][6][7]. The combination reduces symptoms such as cough, runny nose, sneezing, and red, itchy eyes[1][2][3][6][7][10]. The oral solution is contraindicated in children under 2 years due to severe respiratory risks[2][10][11]. Promethazine is structurally a phenothiazine derivative with antihistaminic, anticholinergic, and mild dopamine antagonist action[6][8]. Dextromethorphan is structurally related to morphinan derivatives but devoid of opioid and analgesic properties[7]. The combination is commonly available as an oral solution dosed every 4–6 hours as needed[1][2][3][11].

Brand names
Phen Tuss DMPromethazine DM
Other names
promethazine/dextromethorphanpromethazine HCl/dextromethorphan HBr
02

Targets

NaV (Voltage-gated sodium channels)mAChR (Muscarinic acetylcholine receptors)HRH1 (Histamine H1 Receptor)ADRA1A (α1A)DRD2 (Dopamine D2 Receptor)NMDAR (Glutamate receptor ionotropic, NMDA)

Beyond the preview

Go deeper on dextromethorphan + promethazine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on dextromethorphan + promethazine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call